Genome wide-association studies have clearly shown the key roles of helper T (Th) cells and cellular immune responses for development of multiple sclerosis (MS). Novel medication for a "relapsing-remitting" form of MS (RR-MS) including natalizumab and fingolimod that targets immune cells, such as Th cells, is now available in clinics. However, a significant proportion of RR-MS patients subsequently develop a chronic progressive disease without obvious signs of relapses known as secondary progressive MS (SP-MS). Therapeutic agents for SP-MS are limited and pathogenesis of SP-MS remains elusive, partly because of the lack of experimental animal models that enable comprehensive and deep analysis of the disease.
Introduction
Recent research progress on genome-wide association studies has successfully revealed the involvement of a number of genes significantly associated with the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). 1, 2 Interestingly, most of the susceptibility genes associated with the pathogenesis of MS have been integrated into those involved in the regulation of helper T (Th) cell function and following cellular immune responses. 3 These data clearly show the pivotal roles of acquired immunity, especially regulation and maintenance of differentiation and functions of Th cells on the development of relapsing-remitting MS (RR-MS); that is, an inflammatory cascade triggered by infiltration of pathogenic T cells that secrete interferon (IFN)-c, interleukin (IL)-17, and other inflammatory cytokines promoting demyelination and axonal changes characteristic of MS lesions. [4] [5] [6] Consequently, a better understanding of the pathogenesis of the disease during the past decades has enabled the expansion of disease-modifying therapies from conventional IFN-b that reduces relapse rates and severity through modulation of general immune responses to newly introduced drugs, such as anti-a4 integrin antibody (natarizumab) and S1PR1 agonist (fingolimod), which inhibit the mobilization and accumulation of T cells into the central nervous system (CNS), and glatiramer acetate (copolymer-1), which attenuates excess T-cell activation, probably acting as a decoy for myelin antigens. In contrast, current therapeutic options for progressive forms of MS, including primary progressive MS and secondary progressive MS (SP-MS), remain poor in comparison with those for RR-MS. Furthermore, as diagnosis for SP-MS is based on patients' medical history of neurological deterioration with or without relapses after long-term medical follow up, it remains retrospective in principle. One apparent reason for this is a lack of precise understanding for pathogenic mechanisms driving the progressive form of MS, which enable identification of therapeutic target molecule(s) and reliable biomarker(s). 7 Summarized in the present review article are the novel pathogenic mechanisms of SP-MS based on our recent progress in research for SP-MS pathogenesis, along with possible new therapeutic interventions for the diseases.
Pathogenic mechanism of SP-MS
Prevention of progression in neurological diseases, such as MS and many other neurodegenerative diseases, remain a redoubtable challenge in the field of clinical research. Although it is not well elucidated why and how conversion of the disease from RR-MS to progressive MS happens, inflammation and neurodegeneration, which are not necessarily mutually exclusive, are two key components strongly associated with progressive MS. [8] [9] [10] Currently, CNS-autonomous events associated with neurodegeneration, such as hyperactivation of microglia/astrocyte, mitochondrial injury, glutamate excitotoxicity, loss of trophic support and deficit in axonal transport, are believed to be major components associated with progressive MS. In contrast, the fact that global inflammatory responses in the CNS of SP-MS patients are much milder compared with acute disease makes us underscore the significance of underlying smoldering inflammation for the development and progression of SP-MS. Although sustained lowlevel inflammation is attributed to intermittent stimulation of innate immunity, including activation of microglia and dendritic cells in the CNS, the precise mechanism of this activation remains elusive. 11, 12 By definition, SP-MS is a progressive form of disease preceded by relapsing-remitting symptoms with massive inflammation caused by massive activation of acquired immunity.
Intriguingly, meningeal tertiary lymphoid-like structures are formed only in SP-MS patients, and correlate with the degree of subpial cortical demyelination and brain atrophy, [13] [14] [15] [16] suggesting that activation of acquired immunity in this special compartment might contribute to cortical pathology in SP-MS. 17, 18 A couple of immune components have been reported to cause neuronal cell death, as summarized below.
Clinical severity and apoptosis in brainstem motor neurons are reduced by blocking tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in experimental autoimmune encephalomyelitis (EAE) mice, and myelin-specific T cells isolated from TRAIL-deficient mice show reduced encephalitogenicity. 19 In addition, treatment with soluble TRAIL significantly induces neuronal cell death in human brain slice culture. 20 Furthermore, dying spinal motor neurons are observed to be surrounded by CD4+ and CD8+ T cells expressing TRAIL in both human MS and mouse EAE. 21 Perforin and granzyme A/B secreted by CD8+ (and to a lower degree by CD4+ cells) might induce antigen-dependent neuronal apoptosis. 22 Cytotoxic CD8+ T cells accumulated in ectopic follicle-like structures might be the source of these cytolytic molecules. 18 Fasinduced apoptosis of neuron cells after binding to Fas ligand expressed on CD8+ T cells could be involved in the slow course of the neuronal response leading to a delayed apoptotic killing of neurons in the presence of model antigens derived from lymphocytic choriomeningitis virus envelope glycoprotein. 23 However, another report suggests that Fas ligand expressed on neurons might be protective against perforin-mediated lysis of the plasma membrane by blocking degranulation of CD8+ T cells. 24 Therefore, the role of Fas and Fas ligand in neuronal injury seems to require further investigation. T cell-derived inflammatory cytokines, such as tumor necrosis factor-a, IFN-c and IL-17, sensitize glutamate receptors and increase glutamate excitotoxicity. 25 In a rat model of inflammatory bowel disease, tumor necrosis factor-a is shown to cause vagal neuron apoptosis that is prevented by protease-activated receptor 1 (PAR-1) blockade.
Identification of NR4A2 as an intrinsic component of pathogenic helper T cells in RR-MS and EAE
Animal models for human diseases, such as MS, provide a great opportunity to gain clear-cut insights into underlying pathogenic mechanisms of the disease. The most well accepted animal model for MS is EAE, where mice are immunized with myelin peptides derived from myelin oligodendrocyte glycoprotein (MOG), proteolipid protein and so on emulsified in complete Freund's adjuvant to induce differentiation of autoreactive effector T cells. 28, 29 Once these encephalitogenic T cells infiltrate into the CNS, they secrete inflammatory cytokines, including IL-17 and IFN-c, and recruit other inflammatory immune cells to promote damage to myelin and induce ascending paralysis, a typical symptoms of EAE.
NR4A2, also known as Nurr1, is one of the orphan nuclear receptors that is selectively upregulated in CD4+ T cells derived from RR-MS patients. 30, 31 Interestingly, upregulation of NR4A2 is reproducible in CD4+ T cells infiltrating the CNS and in peripheral blood of mice with EAE. 30, 32 Further analysis showed that NR4A2 plays a critical role in the expression of genes associated with the development of Th17 cells, such as IL-17, IL-23 receptor and IL-21, by Th cells without affecting their expression of Related Orphan Receptor gamma t (RORc t). 32 Consistently, inhibition of NR4A2 expression by small interfering RNA (siRNA) clearly reduced the expression of these cytokines and ameliorated EAE, suggesting that T cell-mediated acute inflammation in EAE is under the control of NR4A2. Systemic treatment with NR4A2-specific siRNA reduced IL-17 production by effector Th cells and protected mice from EAE symptoms.
EAE consists of NR4A2-dependent and -independent phases
Although EAE induced by immunization of C57BL/6 mice with MOG peptide is usually accepted as an animal model of RR-MS with predominant symptoms of demyelination, especially in spinal cord, some EAE models induced by immunization of C57BL/6 mice with myelin basic protein-proteolipid protein fusion protein or by immunization of non-obese diabetic mice with MOG peptide show significant axonal loss with chronic progression of disease severity, suggesting potential application of EAE for analyzing pathogenesis of SP-MS and related neurodegeneration. 33, 34 Further analysis using conditional knockout (cKO) mice of the NR4A2 gene on the B6 background by mating floxed NR4A2 mice and CD4-Cre deleter mice showed that NR4A2cKO mice develop very mild signs of the disease together with reduced accumulation of Th cell in the CNS and their induced production of IL-17, suggesting the crucial role of NR4A2 on the development of EAE. 35 Unexpectedly, NR4A2cKO mice developed EAE-like symptoms a couple of weeks later. Afterwards, both the control and NR4A2cKO mice had an indistinguishable course of EAE with equivalent disease severity. Accordingly, a difference in the numbers of IL-17-producing Th cells in the CNS was not evident during the late/chronic phase of EAE. 35 As EAE induced in C57BL/6 mice after immunization with MOG peptide is supposed to be monophasic, it is rather unusual to observe differential severity of symptoms at different time-points after EAE induction in single gene-deleted mice. Taken together, clinical stages of MOG -induced EAE in C57BL/6 mice can be separated into two phases: (i) an NR4A2-dependent early/acute phase; and (ii) an NR4A2-independent late/chronic phase (Fig. 1) .
Eomesodermin-positive helper T cells as a deteriorating component for late/chronic EAE
Further analysis elucidating potential pathogenic mechanisms operating in the late/chronic phase of EAE revealed that CNS-infiltrating Th cells in late/ chronic EAE show higher expression of the Eomesodermin gene (Eomes). 35 Although it has been broadly appreciated that cytotoxic T cells and natural killer cells express Eomes, Eomes expression by Th cells in the context of autoimmune inflammation has not been previously described. 
Cytotoxic properties of Eomes + Th cells and its relevance to neurodegeneration
As expression of Eomes is associated with the cytotoxic property of CD8+ T cells and natural killer cells, we next examine the cytotoxic potential of Eomes + Th cells that might pave the way to explain neurodegeneration in association with SP-MS. Th cells from late/chronic EAE retain the cytotoxic protease granzyme B and increased surface expression of CD107a as a consequence of lysosome degranulation on stimulation, suggesting that Eomes + Th cells acquire cytotoxic property by their nature. Human Eomes + Th cells from SP-MS patients have been shown to express cytotoxic markers granzyme B and exhibit CD107a mobilization on stimulation. Administration of siRNA, preventing expression of granzyme B gene, significantly ameliorated late/chronic EAE in NR4A2cKO mice, suggesting that Eomes + Th cells are the major source of granzyme B that promotes development of late/chronic EAE. Although cytolytic processes through granzyme expression are usually linked to the co-release of perforin, which supports the incorporation of granzyme into target cells, expression of perforin was scarcely detected in Eomes + Th cells. Instead, a recent report suggests perforin-independent mechanism of cytotoxicity against cultured neuron cells, where granzyme B acts directly on PAR-1, a serine protease-activated G protein-coupled receptor also known as thrombin receptor, expressed by neurons, leading to activation of intracellular caspase pathways and apoptosis of neuron cells. 39 Accordingly, administration of PAR-1 inhibitor clearly inhibited the development of late/ Figure 1 Biphasic pathogenesis of experimental autoimmune encephalomyelitis (EAE). Seemingly monophasic EAE is shown to be composed of mutually independent biphasic symptoms of neuropathology; NR4A2-dependent acute stage and NR4A2-independent (Eomesodermin [Eomes]-dependent) late stage.
chronic EAE, implying that the perforin-independent mechanism of neuronal death can be mediated by granzyme B-PAR-1 interactions ignited by infiltrating Eomes + Th cells. These data raise the possibility that granzyme B-releasing Eomes + Th cells could help to solve the enigma of neurodegeneration associated with pathogenesis of SP-MS (Fig. 2) .
Future perspective
As evidenced by the long history of numerous studies elucidating the pathogenic mechanism of MS, EAE is the one and only useful model for understanding this intractable disease. [4] [5] [6] Despite all the effort, however, we have not paid much attention to the usefulness of this model for unraveling the pathogenesis of chronic CNS inflammation associated with persistent and progressive neurological dysfunctions typically observed in SP-MS. Recently, we have successfully established another scenario for the pathogenesis of SP-MS, in which Eomes + Th cells, previously unappreciated helper T cells with cytotoxic potential for neuron cells, play an essential role for the development of the disease by combining the research on MS samples and its animal model. 35 Interestingly, a large genome-wide association study showed a significant link between Eomes gene polymorphism and the development of MS. 3 It is noteworthy to point out that Siponimod was shown to delay disability progression in patients with SP-MS (the EXPAND study; ECTRIMS meeting at London, 14-17 September 2016), and treatment with ocrelizumab was associated with lower rates of clinical and magnetic resonance imaging progression in patients with primary progressive MS, encouraging us to further pursue the possible involvement of acquired immunity in the pathogenesis of progressive MS. 40 Although the in vivo origin of Eomes + Th cells is still controversial, recent studies have shown that Eomes + Th cells are also generated under chronic inflammatory conditions associated with infection or can be induced in tumor microenvironments by immunomodulation. 41, 42 In addition, pathological studies emphasized the strong association of leptomeningeal formation of ectopic lymphoid follicles with SP-MS. 13, 18, 43 induced in NR4A2cKO mice seems to be strongly associated with the pathogenesis of SP-MS in terms of accumulation of pathogenic Eomes + Th cells, we need to pay attention to the fact that the duration of total disease course is much shorter if compared with SP-MS and thus neuroinflammation at individual time-points should be relatively stronger in mice, which causes differential behavior of immune cells between mice and humans. Furthermore, expression of CXCL13 and BAFF, hallmarks of follicle formation, in the CNS of MOG -immunized C57BL/6 mice was detectable only during the early time-point after disease onset and was quickly decreased at later stages, suggesting that the EAE model of other mouse strains might be required to analyze the relevance between Eomes + Th cells and lymphoid follicle formation in the CNS. 44 Currently, further investigation is underway for fully understanding the pathogenic mechanism for SP-MS. We hope that many MS researchers might pay somewhat more attention to the role of Th cells for the development of SP-MS.
